Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:basedOn |
genetically modified mice
|
| gptkbp:contributedTo |
development of COVID-19 antibody therapies
|
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:enables |
generation of fully human antibodies
rapid antibody candidate identification |
| https://www.w3.org/2000/01/rdf-schema#label |
VelocImmune technology
|
| gptkbp:introducedIn |
2007
|
| gptkbp:license |
gptkb:Bayer
gptkb:AstraZeneca gptkb:Eli_Lilly_and_Company gptkb:Sanofi gptkb:AbbVie gptkb:Amgen gptkb:Roche |
| gptkbp:patent |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:relatedTo |
gptkb:VelociGene_technology
VelociMouse |
| gptkbp:usedFor |
monoclonal antibody discovery
|
| gptkbp:usedIn |
therapeutic antibody development
|
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals_Inc.
|
| gptkbp:bfsLayer |
7
|